Results from studies of the cytotoxic activity of new azolo[5,1-c][1,2,4]triazine derivatives to establish the potential of using them as antitumor agents, including for breast cancer chemotherapy, are presented. The spectral characteristics confirmed that the obtained compounds were highly pure and stable on storage. The cytotoxicity was determined using the methyltetrazolium (MTT) test against MCF-7 and CHO cell lines. The compounds were used at final concentrations from 0.25 to 10.0 μM. Two imidazo[5,1-c][1, 2, 4] triazines (5a and 5d) had calculated half-maximal inhibitory concentrations (IC50) for MCF-7 several times lower than the reference drug epirubicin. The cytotoxicity of all newly synthesized derivatives was lower than that of epirubicin with respect to untransformed CHO cells. This further indicated the potential of these compounds. The results can be used as a basis for selecting compounds 5a and 5d as substances with potential antitumor activity for further studies of their genotoxic and metabolic properties on cell models and laboratory animals.
本文介绍了对新型偶氮并[5,1-c]
[1,2,4]三嗪衍
生物的细胞毒性活性进行研究的结果,以确定将其用作
抗肿瘤药物(包括乳腺癌化疗)的潜力。光谱特征证实了所获化合物的高纯度和储存稳定性。对 MCF-7 和 CHO
细胞系的细胞毒性采用甲基
四氮唑(M
TT)试验进行了测定。化合物的最终浓度为 0.25 至 10.0 μM。经计算,两种
咪唑并[5,1-c][1, 2, 4]三嗪类化合物(5a 和 5d)对 MCF-7 的半数最大抑制浓度(IC50)比参考药物
表柔比星低数倍。对于未转化的 CHO 细胞,所有新合成衍
生物的细胞毒性均低于
表柔比星。这进一步表明了这些化合物的潜力。这些结果可作为选择化合物 5a 和 5d 作为具有潜在抗肿瘤活性物质的依据,以便进一步研究它们在细胞模型和实验动物上的遗传毒性和代谢特性。